Skip to main content

Table 2 MSSES Function and Control scores in non-persistent, persistent, persistent non-adherent, and persistent adherent patients at baseline

From: Glatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study)

 

MSSES Function

Non-persistent (n = 58)

Persistent (n = 131)

Persistent non-adherent (n = 19)

Persistent adherent (n = 112)

Mean (SD) (min.-max.)

689 (173)* (280–900)

752 (156)* (90–900)

715 (182) (240–900)

758 (151) (90–900)

 

MSSES Control

Non-persistent (n = 58)

Persistent (n = 131)

Persistent and non-adherent (n = 19)

Persistent and adherent (n = 112)

Mean (SD) (min.-max.)

491 (192)# (130–900)

568 (178)# (90–900)

560 (140) (210–780)

570 (185) (90–900)

  1. MSSES Multiple Sclerosis Self-Efficacy Scale, min. minimum, max., maximum
  2. *p = 0.0087, # p = 0.0042